2023
Post-diagnosis weight trajectories and mortality among women with breast cancer
Puklin L, Li F, Cartmel B, Zhao J, Sanft T, Lisevick A, Winer E, Lustberg M, Spiegelman D, Sharifi M, Irwin M, Ferrucci L. Post-diagnosis weight trajectories and mortality among women with breast cancer. Npj Breast Cancer 2023, 9: 98. PMID: 38042922, PMCID: PMC10693588, DOI: 10.1038/s41523-023-00603-5.Peer-Reviewed Original ResearchBody mass indexBreast cancer diagnosisWeight changeCause mortalityClinical characteristicsWeight gainWeight lossBreast cancerWeight trajectoriesPost-diagnosis weight changeBreast cancer-specific mortalityCox proportional hazards modelModern treatment eraCancer-specific mortalityCancer diagnosisModerate weight lossModerate weight gainProportional hazards modelAdverse health outcomesElectronic health recordsTreatment eraBaseline characteristicsTumor RegistryMass indexWeight management
2016
Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Research And Treatment 2016, 159: 151-162. PMID: 27484879, DOI: 10.1007/s10549-016-3927-4.Peer-Reviewed Original ResearchConceptsAdjuvant trastuzumabOlder patientsSystemic treatmentBreast cancerHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2HER2-positive diseaseStage III diseaseCongestive heart failureGrowth factor receptor 2Positive breast cancerFactor receptor 2Treatment omissionEndocrine therapyClinical characteristicsSystemic therapyHeart failureBlack patientsTreatment disparitiesTreatment patternsHuman epidermal growth factorEpidermal growth factorMedicare dataPatients
2015
Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer
Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Golshan M, Winer EP, Partridge AH. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals Of Surgical Oncology 2015, 22: 3809-3815. PMID: 25930247, PMCID: PMC4598267, DOI: 10.1245/s10434-015-4572-6.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxietyBody Mass IndexBreast NeoplasmsDecision MakingDirective CounselingFearFemaleGenes, BRCA1Genes, BRCA2Genetic TestingHumansLymphatic MetastasisMastectomy, SegmentalMutationNeoplasm StagingParityPatient ParticipationProphylactic Surgical ProceduresReceptor, ErbB-2RecurrenceTumor BurdenYoung AdultConceptsBreast-conserving surgeryContralateral prophylactic mastectomyEarly-stage breast cancerUnilateral mastectomyBreast cancerYoung womenProphylactic mastectomyUnilateral stage ILarger tumor sizeOngoing cohort studyGood psychosocial supportResultsMedian ageClinical characteristicsCohort studyHER2 positivityNodal involvementLocal therapyLower BMITumor sizeBRCA mutationsPatient-driven decisionSurgical decisionMethodsAs partMultinomial logistic regressionStage I
2011
P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors.
Ligibel J, O'Malley A, Fisher M, Daniel G, Winer E, Keating N. P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors. Cancer Research 2011, 71: p2-17-06-p2-17-06. DOI: 10.1158/0008-5472.sabcs11-p2-17-06.Peer-Reviewed Original ResearchBone density testingBone density evaluationBaseline bone densityAI therapyBone densityDensity testingBone lossAromatase inhibitorsOlder womenHealthCore Integrated Research DatabaseLogistic regressionCommunity-based populationLong-term therapyBreast cancer patientsCommunity-based cohortBone density lossProton pump inhibitorsRisk of fractureLow education levelClinical characteristicsPharmacy dataPump inhibitorsCancer patientsDiagnosis codesAI initiationPathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer
Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Research And Treatment 2011, 131: 1061-1066. PMID: 22080245, DOI: 10.1007/s10549-011-1872-9.Peer-Reviewed Original ResearchConceptsBasal-like carcinomasBreast cancerPathologic featuresYoung womenPatient ageTumor stageMolecular phenotypesInvasive breast cancerLuminal B tumorsPoor prognostic featuresDifferent age groupsClinical characteristicsB tumorsReceptor statusPrognostic featuresCentral reviewMedical recordsTumor gradeHigh prevalenceLarge cohortGeneral populationAge groupsBiomarker expressionCancerHER2Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer?
Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a Sentinel Node Biopsy Be Performed in Patients with High‐Risk Breast Cancer? International Journal Of Breast Cancer 2011, 2011: 973245. PMID: 22295240, PMCID: PMC3262582, DOI: 10.4061/2011/973245.Peer-Reviewed Original ResearchAxillary diseaseSLN biopsyHigh riskNegative SLN biopsy resultsHigh-risk breast cancerNegative SLN biopsySLN biopsy resultsLymph node irradiationSentinel node biopsyBreast cancer patientsAxillary irradiationNode irradiationClinical characteristicsNodal biopsyNodal involvementNode biopsyAdditional surgeryBiopsy resultsCancer patientsBreast cancerBiopsyPatientsBayesian nomogramTest characteristicsDisease
2010
The role of socioeconomic status in adjustment after ductal carcinoma in situ
de Moor JS, Partridge AH, Winer EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer 2010, 116: 1218-1225. PMID: 20143325, PMCID: PMC3072709, DOI: 10.1002/cncr.24832.Peer-Reviewed Original ResearchConceptsLow socioeconomic statusSocioeconomic statusDuctal carcinomaSocial supportTime of enrollmentImpact of SESDCIS diagnosisClinical characteristicsLow financial statusClinical depressionPhysical healthStudy periodFinancial statusWomenDepressionLow SESCarcinomaDistressAnxietyDiagnosisHigher financial statusStatusCurrent studyAssociation
2009
Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study.
Collins L, Collins L, Gelber S, Gelber S, Ruddy K, Ruddy K, Tamimi R, Tamimi R, Come S, Come S, Marotti J, Marotti J, Schapira L, Schapira L, Kereakoglow S, Brachtel E, Brachtel E, Winer E, Winer E, Partridge A, Partridge A. Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. Cancer Research 2009, 69: 6007-6007. DOI: 10.1158/0008-5472.sabcs-09-6007.Peer-Reviewed Original ResearchYoung Women's Breast Cancer StudyBreast Cancer StudyPoor prognostic featuresBasal-like carcinomasPathologic featuresBreast cancerYoung womenHER2 positivityPrognostic featuresTumor stageTumor necrosisER/PR negativityMulti-center prospective cohortInvasive breast cancerClinico-pathologic featuresHER2-positive tumorsCancer studiesHigh tumor gradeHigher tumor stageHigh-grade tumorsBasal-like phenotypeBiomarker expression patternsLogistic regression modelsPR negativityClinical characteristics
2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806
Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H, for the Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research And Treatment 2006, 100: 301-308. PMID: 16773437, DOI: 10.1007/s10549-006-9251-7.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerInterleukin-6Breast cancerP-glycoproteinPgp expressionMultidrug resistance protein-1 expressionSingle-agent paclitaxelElevated serum levelsBreast cancer patientsBreast cancer cell linesProtein-1 expressionResult of cancerMulti-drug resistanceCancer cell linesClinical characteristicsOverall survivalPartial responseSerum levelsTreatment armsWorse prognosisPredictive factorsCancer patientsPredictive markerIHC expressionPaclitaxel sensitivity